Table S1: Research practices and guidance during COVID-19 aligned with statewide conditions and guidance. Phases are listed according to the State of Michigan Safe Start Plan.

	Michigan Safe Start Phases	1 Uncontrolled growth	2 Persistent spread	3 Flattening	4 Improving	5 Containing	6 Post-Pandemic
Statewide Conditions and Guidance	Community transmission status	Increasing new cases every day, likely to overwhelm health system	Continued high case levels, concern about health system capacity	Case growth gradually decreasing	Cases/hospitalizations/ deaths clearly decreasing	Continued case/death rate decreasing, outbreaks quickly contained	Community spread not expected to return
	Control measures	Stay Home, Stay Safe: Strict social distancing, travel restrictions, face coverings, hygiene, remote work	Stay Home, Stay Safe: Strict social distancing, travel reduction, face coverings, hygiene, remote work	Safer at Home: Social distancing, Increasing face coverings, no gatherings	Safer at Home: Social distancing, face coverings, safe workplace practices Small gatherings	Stay Safe: Adherence to new guidelines. social distancing, coverings, mitigated workplaces Increased size gatherings	Sufficient community immunity and availability of treatment
	Permitted activities (Examples)	Critical infrastructure	Critical infrastructure, additional types of recreation allowed	Specified lower-risk businesses with strict safety measures (e.g., manufacturing, outdoor work)	Additional lower-risk businesses with strict safety measures (e.g., retail)	Most businesses with strict mitigation measures, restaurants/ bars, K-12 and higher ed. (live instruction)	No restrictions
Procedures Across Types of Research		Daily health screens, face coverings required, social distancing 6 feet, safety plans, disinfection procedures 2x/daily					None
Wet Lab, Studio and Lab-based Human Research Phase and Density		Lab Phase 0 - Critical and essential research operations including COVID-19, research with potential for immediate impact, other activities for equipment/material maintenance or to ensure safety 250 sq ft/ person for lab that are critical and essential		Lab Phase 1 - Limited capacity 144 sq ft/ person 30% COVID spacing building occupancy Shift work with no intermixing 100% researchers with ~60% total productivity	Lab Phase 2 144 sq ft / person 45% COVID spacing building occupancy Shift work with intermixing with density maintained	Lab Phase 3 144 sq ft/person 60% COVID spacing building occupancy Some office work and small meetings if density allows	No restrictions
Dry Lab/Office/Data Analysis and Computational Work		Remote ≥ 50% remote work					No restrictions
Field Research		Critical and essential research operations only including activities for equipment/material maintenance or to ensure safety		Travel dependent on local conditions No group housing, safety plan		Group housing with public health plan similar to residence halls	No restrictions
Human Research		Tier 0 studies Studies that are entirely concurrent with clinical care conducted entirely by clinical care providers Studies that are entirely remote Approved COVID-19 Studies	Add Tier 1 studies		Add Tier 2 studies	Add Tier 3 studies (*Immunocompromised individuals must remain excluded from Tier 3 studies)	No restrictions

Lumeng JC, Chavous TM, Lok AS, Sen S, Wigginton NS, Cunningham RM. Opinion: A risk-benefit framework for human research during the COVID-19 pandemic. Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):27749-27753. doi: 10.1073/pnas.2020507117. Epub 2020 Oct 21. PMID: 33087558; PMCID: PMC7668055.